Ceramide: Therapeutic potential in combination therapy for cancer treatment

Current Drug Metabolism

Volumn 17, Issue 1, 2016, Pages 37-51

  Li, Feifei ^a   Zhang, Na ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Cancer; Cell apoptosis; Ceramide; Chemotherapeutic drug; Combination therapy; Multidrug resistance

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BORTEZOMIB; CAMPTOTHECIN DERIVATIVE; CERAMIDASE; CERAMIDE; CERAMIDE KINASE; CISPLATIN; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ENTINOSTAT; ETOPOSIDE; FENRETINIDE; FINGOLIMOD; FLUDARABINE; GEMCITABINE; IMATINIB; IRINOTECAN; NILOTINIB; PACLITAXEL; PROTEIN P53; RAPAMYCIN; RESVERATROL; SELUMETINIB; SPHINGOMYELIN SYNTHASE; TAMOXIFEN; TOPOTECAN; UNCLASSIFIED DRUG; VALSPODAR; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL MEMBRANE; CELL NUCLEUS; CELL PERMEABILIZATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIZATION; CYTOPLASM; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG METABOLISM; HUMAN; HYDROPHOBICITY; LIPOPHILICITY; MULTIDRUG RESISTANCE; NANOEMULSION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; NEOPLASMS; PHYSIOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CERAMIDES; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; TREATMENT OUTCOME;

EID: 84954058612     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200216666151103120338     Document Type: Article

References (132)

1. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J. Clin., 2012, 62(5), 457-480.
2. Caley, A.; Jones, R. The principles of cancer treatment by chemotherapy. Surgery (Oxford), 2012, 30(4), 186-190.
3. Kartal-Yandim, M.; Adan-Gokbulut, A.; Baran, Y., Molecular mechanisms of drug resistance and its reversal in cancer. Crit. Rev. Biotechnol., 2015, 1-11.
4. Hutchinson, A. D.; Hosking, J. R.; Kichenadasse, G.; Mattiske, J. K.; Wilson, C. Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat. Rev., 2012, 38(7), 926-934.
5. Mahato, R.; Tai, W.; Cheng, K. Prodrugs for improving tumor targetability and efficiency. Adv. Drug Deliv. Rev. 2011, 63(8), 659-670.
6. Jhaveri, A.; Deshpande, P.; Torchilin, V. Stimuli-sensitive nanopreparations for combination cancer therapy. J. Controlled Release, 2014, 190, 352-370.
7. Liu, Y.; Rohrs, J.; Wang, P. Advances and Challenges in the Use of Nanoparticles to Optimize PK/PD Interactions of Combined Anti-Cancer Therapies. Curr. Drug Metab., 2014, 15(8), 818-828.
8. Friedberg, J. W.; Neuberg, D.; Gribben, J. G.; Fisher, D. C.; Canning, C.; Koval, M.; Poor, C. M.; Green, L. M.; Daley, J.; Soiffer, R.; Ritz, J.; Freedman, A. S. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br. J. Haematol., 2002, 117(4), 828-834.
9. Henry, B.; Moller, C.; Dimanche-Boitrel, M. T.; Gulbins, E.; Becker, K. A. Targeting the ceramide system in cancer. Cancer Lett., 2013, 332(2), 286-294.
10. Saddoughi, S. A.; Ogretmen, B. Diverse functions of ceramide in cancer cell death and proliferation. Adv. Cancer Res., 2013, 117, 37-58.
11. Morad, S. A.; Cabot, M. C. Ceramide-orchestrated signalling in cancer cells. Nat. Rev. Cancer, 2013, 13(1), 51-65.
12. Grosch, S.; Schiffmann, S.; Geisslinger, G. Chain length-specific properties of ceramides. Prog. Lipid Res., 2012, 51(1), 50-62.
13. Levy, M.; Futerman, A. H. Mammalian ceramide synthases. IUBMB Life, 2010, 62(5), 347-356.
14. Stiban, J.; Tidhar, R.; Futerman, A. H., Ceramide synthases: roles in cell physiology and signaling. Adv. Exp. Med. Biol., 2010, 688, 60-71.
15. Hannun, Y. A.; Obeid, L. M. Many ceramides. J. Biol. Chem., 2011, 286(32), 27855-27862.
16. Laviad, E. L.; Albee, L.; Pankova-Kholmyansky, I.; Epstein, S.; Park, H.; Merrill, A. H., Jr.; Futerman, A. H. Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate. J. Biol. Chem. 2008, 283(9), 5677-5684.
17. Mesicek, J.; Lee, H.; Feldman, T.; Jiang, X.; Skobeleva, A.; Berdyshev, E. V.; Haimovitz-Friedman, A.; Fuks, Z.; Kolesnick, R. Ceramide synthases 2, 5, and 6 confer distinct roles in radiation-induced apoptosis in HeLa cells. Cell Signal., 2010, 22(9), 1300-1307.
18. Aureli, M.; Murdica, V.; Loberto, N.; Samarani, M.; Prinetti, A.; Bassi, R.; Sonnino, S. Exploring the link between ceramide and ionizing radiation. Glycoconj. J., 2014, 31(6-7), 449-459.
19. Huwiler, A.; Zangemeister-Wittke, U. Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy. Crit. Rev. Oncol. Hematol., 2007, 63(2), 150-159.
20. Kitatani, K.; Idkowiak-Baldys, J.; Hannun, Y. A. The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell Signal., 2008, 20(6), 1010-1018.
21. Wang, H.; Giuliano, A. E.; Cabot, M. C. Enhanced de novo ceramide generation through activation of serine palmitoyltransferase by the P-glycoprotein antagonist SDZ PSC 833 in breast cancer cells. Mol. Cancer Ther., 2002, 1(9), 719-726.
22. Perry, D. K.; Carton, J.; Shah, A. K.; Meredith, F.; Uhlinger, D. J.; Hannun, Y. A. Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis. J. Biol. Chem., 2000, 275(12), 9078-9084.
23. Scarlatti, F.; Sala, G.; Somenzi, G.; Signorelli, P.; Sacchi, N.; Ghidoni, R. Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling. FASEB J., 2003, 17(15), 2339-2941.
24. Bose, R.; Verheij, M.; Haimovitz-Friedman, A.; Scotto, K.; Fuks, Z.; Kolesnick, R. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell, 1995, 82(3), 405-414.
25. Biswal, S. S.; Datta, K.; Acquaah-Mensah, G. K.; Kehrer, J. P. Changes in ceramide and sphingomyelin following fludarabine treatment of human chronic B-cell leukemia cells. Toxicology, 2000, 154(1-3), 45-53.
26. Modrak, D. E.; Cardillo, T. M.; Newsome, G. A.; Goldenberg, D. M.; Gold, D. V. Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancer. Cancer Res., 2004, 64(22), 8405-8410.
27. Arana, L.; Gangoiti, P.; Ouro, A.; Trueba, M.; Gomez-Munoz, A. Ceramide and ceramide 1-phosphate in health and disease. Lipids Health Dis., 2010, 9, 15.
28. Yeang, C.; Ding, T.; Chirico, W. J.; Jiang, X. C. Subcellular targeting domains of sphingomyelin synthase 1 and 2. Nutr. Metab. (Lond)., 2011, 8, 89.
29. Song, M.; Zang, W.; Zhang, B.; Cao, J.; Yang, G. GCS overexpression is associated with multidrug resistance of human HCT-8 colon cancer cells. J. Exp. Clin. Cancer Res., 2012, 31, 23.
30. Niino, S.; Nakamura, Y.; Hirabayashi, Y.; Nagano-Ito, M.; Ichikawa, S. A small molecule inhibitor of Bcl-2, HA14-1, also inhibits ceramide glucosyltransferase. Biochem. Biophys. Res. Commun., 2013, 433(2), 170-174.
31. Santos, W. L.; Lynch, K. R. Drugging sphingosine kinases. ACS Chem. Biol., 2015, 10(1), 225-233.
32. Abuhusain, H. J.; Matin, A.; Qiao, Q.; Shen, H.; Kain, N.; Day, B. W.; Stringer, B. W.; Daniels, B.; Laaksonen, M. A.; Teo, C.; McDonald, K. L.; Don, A. S. A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis. J. Biol. Chem., 2013, 288(52), 37355-37364.
33. Czubowicz, K.; Strosznajder, R. Ceramide in the molecular mechanisms of neuronal cell death. The role of sphingosine-1-phosphate. Mol. Neurobiol., 2014, 50(1), 26-37.
34. Bektas, M.; Jolly, P. S.; Muller, C.; Eberle, J.; Spiegel, S.; Geilen, C. C. Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression. Oncogene, 2005, 24(1), 178-187.
35. Gomez-Munoz, A.; Gangoiti, P.; Arana, L.; Ouro, A.; Rivera, I. G.; Ordonez, M.; Trueba, M. New insights on the role of ceramide 1-phosphate in inflammation. Biochim. Biophys. Acta, 2013, 1831(6), 1060-1066.
36. Gangoiti, P.; Bernacchioni, C.; Donati, C.; Cencetti, F.; Ouro, A.; Gomez-Munoz, A.; Bruni, P. Ceramide 1-phosphate stimulates proliferation of C2C12 myoblasts. Biochimie, 2012, 94(3), 597-607.
37. Mukhopadhyay, A.; Saddoughi, S. A.; Song, P.; Sultan, I.; Ponnusamy, S.; Senkal, C. E.; Snook, C. F.; Arnold, H. K.; Sears, R. C.; Hannun, Y. A.; Ogretmen, B. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J., 2009, 23(3), 751-763.
38. Oaks, J.; Ogretmen, B. Regulation of PP2A by Sphingolipid Metabolism and Signaling. Front. Oncol., 2014, 4, 388.
39. Tsuruta, F.; Sunayama, J.; Mori, Y.; Hattori, S.; Shimizu, S.; Tsujimoto, Y.; Yoshioka, K.; Masuyama, N.; Gotoh, Y. JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J., 2004, 23(8), 1889-1899.
40. Kim, H. J.; Oh, J. E.; Kim, S. W.; Chun, Y. J.; Kim, M. Y. Ceramide induces p38 MAPK-dependent apoptosis and Bax translocation via inhibition of Akt in HL-60 cells. Cancer Lett., 2008, 260(1-2), 88-95.
41. Bourbon, N. A.; Sandirasegarane, L.; Kester, M. Ceramide-induced inhibition of Akt is mediated through protein kinase Czeta: implications for growth arrest. J. Biol. Chem., 2002, 277(5), 3286-3292.
42. Deng, X.; Gao, F.; May, W. S. Protein phosphatase 2A inactivates Bcl2's antiapoptotic function by dephosphorylation and up-regulation of Bcl2-p53 binding. Blood, 2009, 113(2), 422-428.
43. Carnero, A.; Blanco-Aparicio, C.; Renner, O.; Link, W.; Leal, J. F. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr. Cancer Drug Targets, 2008, 8(3), 187-198.
44. Goswami, R.; Singh, D.; Phillips, G.; Kilkus, J.; Dawson, G. Ceramide regulation of the tumor suppressor phosphatase PTEN in rafts isolated from neurotumor cell lines. J. Neurosci. Res., 2005, 81(4), 541-550.
45. Chang, K. T.; Anishkin, A.; Patwardhan, G. A.; Beverly, L. J.; Siskind, L. J.; Colombini, M. Ceramide channels: destabilization by Bcl-xL and role in apoptosis. Biochim. Biophys. Acta, 2015, 1848(10 Pt A), 2374-2384.
46. Siskind, L. J.; Kolesnick, R. N.; Colombini, M. Ceramide forms channels in mitochondrial outer membranes at physiologically relevant concentrations. Mitochondrion, 2006, 6(3), 118-125.
47. Von Haefen, C.; Wieder, T.; Gillissen, B.; Starck, L.; Graupner, V.; Dorken, B.; Daniel, P. T. Ceramide induces mitochondrial activation and apoptosis via a Bax-dependent pathway in human carcinoma cells. Oncogene, 2002, 21(25), 4009-4019.
48. Ganesan, V.; Perera, M. N.; Colombini, D.; Datskovskiy, D.; Chadha, K.; Colombini, M. Ceramide and activated Bax act synergistically to permeabilize the mitochondrial outer membrane. Apoptosis, 2010, 15(5), 553-562.
49. Sumitomo, M.; Ohba, M.; Asakuma, J.; Asano, T.; Kuroki, T.; Asano, T.; Hayakawa, M. Protein kinase Cdelta amplifies ceramide formation via mitochondrial signaling in prostate cancer cells. J. Clin. Invest., 2002, 109(6), 827-836.
50. Sanvicens, N.; Cotter, T. G. Ceramide is the key mediator of oxidative stress-induced apoptosis in retinal photoreceptor cells. J. Neurochem., 2006, 98(5), 1432-1444.
51. Lin, C. F.; Chen, C. L.; Chiang, C. W.; Jan, M. S.; Huang, W. C.; Lin, Y. S. GSK-3beta acts downstream of PP2A and the PI 3-kinase-Akt pathway, and upstream of caspase-2 in ceramide-induced mitochondrial apoptosis. J. Cell Sci., 2007, 120(Pt 16), 2935-2943.
52. Honorat, M.; Falson, P.; Terreux, R.; Di Pietro, A.; Dumontet, C.; Payen, L. Multidrug Resistance ABC Transporter Structure Predictions by Homology Modeling Approaches. Curr. Drug Metab., 2011, 12(3), 268-277.
53. Van Vlerken, L. E.; Duan, Z.; Seiden, M. V.; Amiji, M. M. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res., 2007, 67(10), 4843-4850.
54. Chen, Y. K.; Tang, Y.; Guo, C. X.; Wang, J. H.; Boral, D.; Nie, D. T. Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem. Pharmacol., 2012, 83(8), 1112-1126.
55. Liu, Y. Y.; Han, T. Y.; Giuliano, A. E.; Cabot, M. C. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J., 2001, 15(3), 719-730.
56. Wang, Y.; Ding, Y.; Liu, Z.; Liu, X.; Chen, L.; Yan, W. Bioactive lipids-based pH sensitive micelles for co-delivery of doxorubicin and ceramide to overcome multidrug resistance in leukemia. Pharm. Res., 2013, 30(11), 2902-2916.
57. Devalapally, H.; Duan, Z.; Seiden, M. V.; Amiji, M. M. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin. Cancer Res., 2008, 14(10), 3193-3203.
58. Sentelle, R. D.; Senkal, C. E.; Jiang, W.; Ponnusamy, S.; Gencer, S.; Selvam, S. P.; Ramshesh, V. K.; Peterson, Y. K.; Lemasters, J. J.; Szulc, Z. M.; Bielawski, J.; Ogretmen, B. Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy. Nat. Chem. Biol., 2012, 8(10), 831-838.
59. Edinger, A. L. Starvation in the midst of plenty: making sense of ceramide-induced autophagy by analysing nutrient transporter expression. Biochem. Soc. Trans., 2009, 37(Pt 1), 253-258.
60. Scarlatti, F.; Bauvy, C.; Ventruti, A.; Sala, G.; Cluzeaud, F.; Vandewalle, A.; Ghidoni, R.; Codogno, P. Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1. J. Biol. Chem. 2004, 279(18), 18384-18391.
61. Li, D. D.; Wang, L. L.; Deng, R.; Tang, J.; Shen, Y.; Guo, J. F.; Wang, Y.; Xia, L. P.; Feng, G. K.; Liu, Q. Q.; Huang, W. L.; Zeng, Y. X.; Zhu, X. F. The pivotal role of c-Jun. NH2-terminal kinase-mediated Beclin 1 expression during anticancer agents-induced autophagy in cancer cells. Oncogene, 2009, 28(6), 886-898.
62. Liu, Y. Y. Resuscitating wild-type p53 expression by disrupting ceramide glycosylation: a novel approach to target mutant p53 tumors. Cancer Res., 2011, 71(20), 6295-6299.
63. Liu, Y. Y.; Patwardhan, G. A.; Bhinge, K.; Gupta, V.; Gu, X.; Jazwinski, S. M. Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells. Cancer Res., 2011, 71(6), 2276-2285.
64. Patwardhan, G. A.; Hosain, S. B.; Liu, D. X.; Khiste, S. K.; Zhao, Y.; Bielawski, J.; Jazwinski, S. M.; Liu, Y. Y. Ceramide modulates pre-mRNA splicing to restore the expression of wild-type tumor suppressor p53 in deletion-mutant cancer cells. Biochim. Biophys. Acta, 2014, 1841(11), 1571-1580.
65. Aouali, N.; Eddabra, L.; Macadre, J.; Morjani, H. Immunosuppressors and reversion of multidrug-resistance. Crit. Rev. Oncol. Hematol., 2005, 56(1), 61-70.
66. Cabot, M. C.; Giuliano, A. E.; Han, T. Y.; Liu, Y. Y. SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells. Cancer Res., 1999, 59(4), 880-885.
67. Filipski, E.; Berland, E.; Ozturk, N.; Guettier, C.; Van Der Horst, G. T.; Levi, F.; Okyar, A. Optimization of irinotecan chronotherapy with P-glycoprotein inhibition. Toxicol. Appl. Pharmacol., 2014, 274(3), 471-479.
68. Mimeault, M.; Venkatraman, G.; Johansson, S. L.; Moore, E.; Henichart, J. P.; Depreux, P.; Lin, M. F.; Batra, S. K. Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide. Int. J. Cancer, 2007, 120(1), 160-169.
69. Park, S. R.; Cho, H. J.; Moon, K. J.; Chun, K. H.; Kong, S. Y.; Yoon, S. S.; Lee, J. S.; Park, S. Cytotoxic effects of novel phytosphingosine derivatives, including N, N-dimethylphytosphingosine and N-monomethylphytosphingosine, in human leukemia cell line HL60. Leuk. Lymphoma, 2010, 51(1), 132-45.
70. Gojo, I.; Karp, J. E.; Mann, D.; Rollins, S.; Greer, J.; Tidwell, M. L.; Zhai, S. P.; Figg, W. D.; Trepel, J.; Ryan, Q.; Sausville, E. Phase I study of histone deacetylase inhibitor (HDI) MS-275 in adults with refractory or relapsed hematologic malignancies. Blood, 2002, 100(11), 559a.
71. Maggio, S. C.; Rosato, R. R.; Kramer, L. B.; Dai, Y.; Rahmani, M.; Paik, D. S.; Czarnik, A. C.; Payne, S. G.; Spiegel, S.; Grant, S. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res., 2004, 64(7), 2590-2600.
72. Rehman, F.; Shanmugasundaram, P.; Schrey, M. P. Fenretinide stimulates redox-sensitive ceramide production in breast cancer cells: potential role in drug-induced cytotoxicity. Br. J. Cancer, 2004, 91(10), 1821-1828.
73. Mody, N.; McIlroy, G. D. The mechanisms of Fenretinide-mediated anti-cancer activity and prevention of obesity and type-2 diabetes. Biochem. Pharmacol. 2014, 91(3), 277-286.
74. Senkal, C. E.; Ponnusamy, S.; Rossi, M. J.; Bialewski, J.; Sinha, D.; Jiang, J. C.; Jazwinski, S. M.; Hannun, Y. A.; Ogretmen, B. Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas. Mol. Cancer Ther., 2007, 6(2), 712-722.
75. Saddoughi, S. A.; Garrett-Mayer, E.; Chaudhary, U.; O'Brien, P. E.; Afrin, L. B.; Day, T. A.; Gillespie, M. B.; Sharma, A. K.; Wilhoit, C. S.; Bostick, R.; Senkal, C. E.; Hannun, Y. A.; Bielawski, J.; Simon, G. R.; Shirai, K.; Ogretmen, B. Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C (1) (8)-ceramide as a novel biomarker for monitoring response. Clin. Cancer Res., 2011, 17(18), 6097-6105.
76. Lucci, A.; Han, T. Y.; Liu, Y. Y.; Giuliano, A. E.; Cabot, M. C. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells. Cancer, 1999, 86(2), 300-311.
77. Yun, S. H.; Park, E. S.; Shin, S. W.; Ju, M. H.; Han, J. Y.; Jeong, J. S.; Kim, S. H.; Stonik, V. A.; Kwak, J. Y.; Park, J. I. By activating Fas/ceramide synthase 6/p38 kinase in lipid rafts, stichoposide D inhibits growth of leukemia xenografts. Oncotarget, 2015, 6(29), 27596-27612.
78. Abe, A.; Wild, S. R.; Lee, W. L.; Shayman, J. A. Agents for the treatment of glycosphingolipid storage disorders. Curr. Drug Metab. 2001, 2(3), 331-338.
79. Wang, T.; Wei, J.; Wang, N.; Ma, J. L.; Hui, P. P. The glucosylceramide synthase inhibitor PDMP sensitizes pancreatic cancer cells to MEK/ERK inhibitor AZD-6244. Biochem. Biophys. Res. Commun., 2015, 456(3), 821-826.
80. Huang, W. C.; Tsai, C. C.; Chen, C. L.; Chen, T. Y.; Chen, Y. P.; Lin, Y. S.; Lu, P. J.; Lin, C. M.; Wang, S. H.; Tsao, C. W.; Wang, C. Y.; Cheng, Y. L.; Hsieh, C. Y.; Tseng, P. C.; Lin, C. F. Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis. FASEB J., 2011, 25(10), 3661-3673.
81. Gong, L.; Yang, B.; Xu, M.; Cheng, B.; Tang, X.; Zheng, P.; Jing, Y.; Wu, G. J. Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide production. Cancer Chemother. Pharmacol., 2014, 73(1), 69-77.
82. Sietsma, H.; Veldman, R. J.; Kolk, D.; Ausema, B.; Nijhof, W.; Kamps, W.; Vellenga, E.; Kok, J. W. 1-phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine. Clin. Cancer Res., 2000, 6(3), 942-948.
83. Dijkhuis, A. J.; Klappe, K.; Jacobs, S.; Kroesen, B. J.; Kamps, W.; Sietsma, H.; Kok, J. W. PDMP sensitizes neuroblastoma to paclitaxel by inducing aberrant cell cycle progression leading to hyperploidy. Mol. Cancer Ther., 2006, 5(3), 593-601.
84. Kartal, M.; Saydam, G.; Sahin, F.; Baran, Y. Resveratrol triggers apoptosis through regulating ceramide metabolizing genes in human K562 chronic myeloid leukemia cells. Nutr. Cancer, 2011, 63(4), 637-644.
85. Maurer, B. J.; Melton, L.; Billups, C.; Cabot, M. C.; Reynolds, C. P. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl) retinamide and modulators of ceramide metabolism. J. Natl. Cancer Inst., 2000, 92(23), 1897-1909.
86. Devalapally, H.; Duan, Z. F.; Seiden, M. V.; Amiji, M. M. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin. Cancer Res., 2008, 14(10), 3193-3203.
87. Awad, A. B.; Barta, S. L.; Fink, C. S.; Bradford, P. G. beta-Sitosterol enhances tamoxifen effectiveness on breast cancer cells by affecting ceramide metabolism. Mol. Nutr. Food Res., 2008, 52(4), 419-426.
88. Roberts, C. G.; Gurisik, E.; Biden, T. J.; Sutherland, R. L.; Butt, A. J. Synergistic cytotoxicity between tamoxifen and the plant toxin persin in human breast cancer cells is dependent on Bim expression and mediated by modulation of ceramide metabolism. Mol. Cancer Ther., 2007, 6(10), 2777-2785.
89. Batra, S.; Reynolds, C. P.; Maurer, B. J. Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Res., 2004, 64(15), 5415-5424.
90. Gouaze-Andersson, V.; Flowers, M.; Karimi, R.; Fabrias, G.; Delgado, A.; Casas, J.; Cabot, M. C. Inhibition of acid ceramidase by a 2-substituted aminoethanol amide synergistically sensitizes prostate cancer cells to N-(4-hydroxyphenyl) retinamide. Prostate, 2011, 71(10), 1064-1073.
91. Noack, J.; Choi, J.; Richter, K.; Kopp-Schneider, A.; Regnier-Vigouroux, A. A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy. Cell Death Dis., 2014, 5, e1425.
92. Yang, Y. L.; Ji, C.; Cheng, L.; He, L.; Lu, C. C.; Wang, R.; Bi, Z. G. Sphingosine kinase-1 inhibition sensitizes curcumin-induced growth inhibition and apoptosis in ovarian cancer cells. Cancer Sci., 2012, 103(8), 1538-1545.
93. Chatzakos, V.; Rundlof, A. K.; Ahmed, D.; De Verdier, P. J.; Flygare, J. Inhibition of sphingosine kinase 1 enhances cytotoxicity, ceramide levels and ROS formation in liver cancer cells treated with selenite. Biochem. Pharmacol., 2012, 84(5), 712-721.
94. Shin, K. O.; Park, N. Y.; Seo, C. H.; Hong, S. P.; Oh, K. W.; Hong, J. T.; Han, S. K.; Lee, Y. M. Inhibition of sphingolipid metabolism enhances resveratrol chemotherapy in human gastric cancer cells. Biomol. Ther. (Seoul), 2012, 20(5), 470-476.
95. Yin, G. J.; Lan, K. H.; Hu, C. Y.; Lu, Q.; Tang, W.; Wang, S. F. Antitumor effect of sphingosine kinase 1 inhibitor in combination with chemotherapy on SGC7901 gastric cancer cells in vitro. Zhonghua Zhong Liu Za Zhi, 2012, 34(2), 96-99.
96. Wang, H.; Maurer, B. J.; Liu, Y. Y.; Wang, E.; Allegood, J. C.; Kelly, S.; Symolon, H.; Liu, Y.; Merrill, A. H., Jr.; Gouaze-Andersson, V.; Yu, J. Y.; Giuliano, A. E.; Cabot, M. C. N-(4-Hydroxyphenyl) retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing. Mol. Cancer Ther., 2008, 7(9), 2967-2976.
97. Hu, Y.; Li, C.; Li, H.; Li, M.; Shu, X. Resveratrol-mediated reversal of tumor multi-drug resistance. Curr. Drug Metab., 2014, 15(7), 703-710.
98. Xing, Y.; Wang, Z. H.; Ma, D. H.; Han, Y. FTY720 enhances chemosensitivity of colon cancer cells to doxorubicin and etoposide via the modulation of P-glycoprotein and multidrug resistance protein 1. J. Dig. Dis., 2014, 15(5), 246-259.
99. Zheng, T.; Meng, X.; Wang, J.; Chen, X.; Yin, D.; Liang, Y.; Song, X.; Pan, S.; Jiang, H.; Liu, L. PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice. J. Cell Biochem., 2010, 111(1), 218-28.
100. Ishitsuka, A.; Fujine, E.; Mizutani, Y.; Tawada, C.; Kanoh, H.; Banno, Y.; Seishima, M. FTY720 and cisplatin synergistically induce the death of cisplatin-resistant melanoma cells through the downregulation of the PI3K pathway and the decrease in epidermal growth factor receptor expression. Int. J. Mol. Med., 2014, 34(4), 1169-1174.
101. Shen, Y.; Wang, X.; Xia, W.; Wang, C.; Cai, M.; Xie, H.; Zhou, L.; Zheng, S. Antiproliferative and overadditive effects of rapamycin and FTY720 in pancreatic cancer cells in vitro. Transplant. Proc., 2008, 40(5), 1727-1733.
102. Li, M. H.; Hla, T.; Ferrer, F. FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway. Pediatr. Blood Cancer, 2013, 60(9), 1418-1423.
103. Yasui, H.; Hideshima, T.; Raje, N.; Roccaro, A. M.; Shiraishi, N.; Kumar, S.; Hamasaki, M.; Ishitsuka, K.; Tai, Y. T.; Podar, K.; Catley, L.; Mitsiades, C. S.; Richardson, P. G.; Albert, R.; Brinkmann, V.; Chauhan, D.; Anderson, K. C. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res., 2005, 65(16), 7478-7484.
104. Pastukhov, O.; Schwalm, S.; Zangemeister-Wittke, U.; Fabbro, D.; Bornancin, F.; Japtok, L.; Kleuser, B.; Pfeilschifter, J.; Huwiler, A., The ceramide kinase inhibitor NVP-231 inhibits breast and lung cancer cell proliferation by inducing M phase arrest and subsequent cell death. Br. J. Pharmacol., 2014, 171(24), 5829-5844.
105. Barth, B. M.; Cabot, M. C.; Kester, M. Ceramide-based therapeutics for the treatment of cancer. Anticancer Agents Med. Chem., 2011, 11(9), 911-919.
106. Stover, T. C.; Sharma, A.; Robertson, G. P.; Kester, M. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin. Cancer Res., 2005, 11(9), 3465-3474.
107. Liu, X.; Ryland, L.; Yang, J.; Liao, A.; Aliaga, C.; Watts, R.; Tan, S. F.; Kaiser, J.; Shanmugavelandy, S. S.; Rogers, A.; Loughran, K.; Petersen, B.; Yuen, J.; Meng, F.; Baab, K. T.; Jarbadan, N. R.; Broeg, K.; Zhang, R.; Liao, J.; Sayers, T. J.; Kester, M.; Loughran, T. P., Jr. Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood, 2010, 116(20), 4192-4201.
108. Tagaram, H. R.; Divittore, N. A.; Barth, B. M.; Kaiser, J. M.; Avella, D.; Kimchi, E. T.; Jiang, Y.; Isom, H. C.; Kester, M.; Staveley-O'Carroll, K. F. Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma. Gut, 2011, 60(5), 695-701.
109. Ganta, S.; Singh, A.; Patel, N. R.; Cacaccio, J.; Rawal, Y. H.; Davis, B. J.; Amiji, M. M.; Coleman, T. P. Development of EGFR-targeted nanoemulsion for imaging and novel platinum therapy of ovarian cancer. Pharm. Res., 2014, 31(9), 2490-2502.
110. Zhu, X.; Du, X.; Deng, X.; Yi, H.; Cui, S.; Liu, W.; Shen, A.; Cui, Z. C6 ceramide sensitizes pemetrexed-induced apoptosis and cytotoxicity in osteosarcoma cells. Biochem. Biophys. Res. Commun., 2014, 452(1), 72-78.
111. Ji, C.; Yang, Y. L.; He, L.; Gu, B.; Xia, J. P.; Sun, W. L.; Su, Z. L.; Chen, B.; Bi, Z. G. Increasing ceramides sensitizes genistein-induced melanoma cell apoptosis and growth inhibition. Biochem. Biophys. Res. Commun., 2012, 421(3), 462-467.
112. Fonseca, N. A.; Gomes-Da-Silva, L. C.; Moura, V.; Simoes, S.; Moreira, J. N. Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination. J. Control Release, 2014, 196, 122-131.
113. Tran, M. A.; Smith, C. D.; Kester, M.; Robertson, G. P. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin. Cancer Res., 2008, 14(11), 3571-3581.
114. Best, C.; Calianese, D.; Szulak, K.; Cammarata, G.; Brum, G.; Carbone, T.; Still, E.; Higgins, K.; Ji, F.; Di, W.; Wanebo, H.; Wan, Y. Paclitaxel disrupts polarized entry of membrane-permeable C6 ceramide into ovarian cancer cells resulting in synchronous induction of cell death. Oncol. Lett., 2013, 5(6), 1854-1858.
115. Zhu, Q. Y.; Wang, Z.; Ji, C.; Cheng, L.; Yang, Y. L.; Ren, J.; Jin, Y. H.; Wang, Q. J.; Gu, X. J.; Bi, Z. G.; Hu, G.; Yang, Y. C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and alpha-tubulin hyperacetylation both in vitro and in vivo. Cell Death Dis., 2011, 2, e117.
116. Feng, L. X.; Li, M.; Liu, Y. J.; Yang, S. M.; Zhang, N. Synergistic enhancement of cancer therapy using a combination of ceramide and docetaxel. Int. J. Mol. Sci., 2014, 15(3), 4201-4220.
117. Morad, S. A.; Madigan, J. P.; Levin, J. C.; Abdelmageed, N.; Karimi, R.; Rosenberg, D. W.; Kester, M.; Shanmugavelandy, S. S.; Cabot, M. C. Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53. Biochem. Pharmacol., 2013, 85(8), 1057-1065.
118. Chapman, J. V.; Gouaze-Andersson, V.; Karimi, R.; Messner, M. C.; Cabot, M. C. P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells. Exp. Cell. Res., 2011, 317(12), 1736-1745.
119. Morad, S. A.; Levin, J. C.; Shanmugavelandy, S. S.; Kester, M.; Fabrias, G.; Bedia, C.; Cabot, M. C. Ceramide-antiestrogen nanoliposomal combinations-novel impact of hormonal therapy in hormone-insensitive breast cancer. Mol. Cancer Ther., 2012, 11(11), 2352-2361.
120. Adiseshaiah, P. P.; Clogston, J. D.; McLeland, C. B.; Rodriguez, J.; Potter, T. M.; Neun, B. W.; Skoczen, S. L.; Shanmugavelandy, S. S.; Kester, M.; Stern, S. T.; McNeil, S. E. Synergistic combination therapy with nanoliposomal C6-ceramide and vinblastine is associated with autophagy dysfunction in hepatocarcinoma and colorectal cancer models. Cancer Lett., 2013, 337(2), 254-265.
121. Chen, J. Y.; Hwang, C. C.; Chen, W. Y.; Lee, J. C.; Fu, T. F.; Fang, K.; Chu, Y. C.; Huang, Y. L.; Lin, J. C.; Tsai, W. H.; Chang, H. W.; Chen, B. H.; Chiu, C. C. Additive effects of C (2)-ceramide on paclitaxel-induced premature senescence of human lung cancer cells. Life Sci., 2010, 87(11-12), 350-357.
122. Senkal, C. E.; Ponnusamy, S.; Rossi, M. J.; Sundararaj, K.; Szulc, Z.; Bielawski, J.; Bielawska, A.; Meyer, M.; Cobanoglu, B.; Koybasi, S.; Sinha, D.; Day, T. A.; Obeid, L. M.; Hannun, Y. A.; Ogretmen, B. Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo. J. Pharmacol. Exp. Ther., 2006, 317(3), 1188-1199.
123. Stover, T.; Kester, M. Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells. J. Pharmacol. Exp. Ther., 2003, 307(2), 468-475.
124. Kester, M.; Heakal, Y.; Fox, T.; Sharma, A.; Robertson, G. P.; Morgan, T. T.; Altinoglu, E. I.; Tabakovic, A.; Parette, M. R.; Rouse, S. M.; Ruiz-Velasco, V.; Adair, J. H. Calcium phosphate nanocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cells. Nano. Lett., 2008, 8(12), 4116-4121.
125. Morgan, T. T.; Muddana, H. S.; Altinoglu, E. I.; Rouse, S. M.; Tabakovic, A.; Tabouillot, T.; Russin, T. J.; Shanmugavelandy, S. S.; Butler, P. J.; Eklund, P. C.; Yun, J. K.; Kester, M.; Adair, J. H. Encapsulation of organic molecules in calcium phosphate nanocomposite particles for intracellular imaging and drug delivery. Nano. Lett., 2008, 8(12), 4108-4115.
126. Stover, T. C.; Kim, Y. S.; Lowe, T. L.; Kester, M. Thermoresponsive and biodegradable linear-dendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug. Biomaterials, 2008, 29(3), 359-369.
127. Ganta, S.; Singh, A.; Kulkarni, P.; Keeler, A. W.; Piroyan, A.; Sawant, R. R.; Patel, N. R.; Davis, B.; Ferris, C.; O'Neal, S.; Zamboni, W.; Amiji, M. M.; Coleman, T. P. EGFR Targeted Theranostic Nanoemulsion for Image-Guided Ovarian Cancer Therapy. Pharm. Res., 2015, 32(8), 2753-2763.
128. Deshpande, D.; Devalapally, H.; Amiji, M. Enhancement in anti-proliferative effects of paclitaxel in aortic smooth muscle cells upon co-administration with ceramide using biodegradable polymeric nanoparticles. Pharm. Res., 2008, 25(8), 1936-1947.
129. Devalapally, H.; Duan, Z.; Seiden, M. V.; Amiji, M. M. Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int. J. Cancer, 2007, 121(8), 1830-1838.
130. Van Vlerken, L. E.; Duan, Z. F.; Seiden, M. V.; Amiji, M. M. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res., 2007, 67(10), 4843-4850.
131. Dickson, M. A.; Carvajal, R. D.; Merrill, A. H., Jr.; Gonen, M.; Cane, L. M.; Schwartz, G. K. A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin. Cancer Res., 2011, 17(8), 2484-2492.
132. Gouaze-Andersson, V.; Yu, J. Y.; Kreitenberg, A. J.; Bielawska, A.; Giuliano, A. E.; Cabot, M. C. Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells. Biochim. Biophys. Acta, 2007, 1771(12), 1407-1417.